X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
CTx-2103, a novel, trimodal, extended-release tablet of buspirone hydrochloride is being studied for the treatment of anxiety. Buspirone, an azapirone derivative and a 5-HT1A partial agonist, was the first non-benzodiazepine anxiolytic introduced for anxiety disorder.
Lead Product(s): Buspirone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: CTx-2103
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2022
Details:
CTx-2103 contains the active pharmaceutical ingredient buspirone hydrochloride, a non-benzodiazepine medication, which has no evidence for the development or risk of dependency.
Lead Product(s): Buspirone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: CTx-2103
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2022
Details:
CTx-2103 (Buspirone Hydrochloride) is a novel, trimodal, extended-release tablet of buspirone incorporating Cingulate’s proprietary PTR™ drug delivery platform, and is being studied for the treatment of anxiety and/or anxiety-related disorders.
Lead Product(s): Buspirone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: CTx-2103
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: BDD Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
